Descriptive only

Suicidal ideation or behavior

Overweight or obesity without diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)

Randomized trials

Treatments

924

Participants

Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 4 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

NoteOutcome assessment, time point: selected time points span 27 to 111 weeks
NoteOutcome assessment, definition: mixed: not stated 3, postbaseline suicidal ideation on C-SSRS 1
NoteData handling, input conversions: arms_combined 1

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
STEP 5	111	safety	postbaseline suicidal ideation on C-SSRS	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent
NCT04904913	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Chinese adults 18 to 75; BMI 28 or more, or 24 or more with comorbidity or hyperphagia; no diabetes, HbA1c below 6.5
NCT05623839	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 70; BMI 27 to 50; HbA1c below 6.5 percent; no diabetes
NCT06256562	33	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 75; BMI 24 to <28 kg/m2 with comorbidity or 28 or more (Chinese criteria); no diabetes

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
STEP 5	A1	SEMA_SC_2p4MG_QW	111	arm, events	1 / 152		R0019370:Table 3
STEP 5	A2	PLACEBO	111	arm, events	2 / 152		R0019370:Table 3
NCT04904913	A1	MAZD_SC_3MG_QW	36	arm, events	0 / 62		R0016107:Results
NCT04904913	A2	MAZD_SC_4p5MG_QW	36	arm, events	0 / 63		R0016107:Results
NCT04904913	A3	MAZD_SC_6MG_QW	36	arm, events	0 / 61		R0016107:Results
NCT04904913	A4	PLACEBO	36	arm, events	0 / 62		R0016107:Results
NCT05623839	A1	PLACEBO	27	arm, events	0 / 8		R0013210:Supplement Table S2
NCT05623839	A2+A3	MAZD_SC_16MG_QW	27	arm, events	0 / 24	arms_combined	R0013210:Supplement Table S2
NCT06256562	A1	BOFANG_SC_12MG_Q2W	33	arm, events	0 / 52		R0002409:Results
NCT06256562	A2	BOFANG_SC_18MG_Q2W	33	arm, events	0 / 53		R0002409:Results
NCT06256562	A3	BOFANG_SC_24MG_Q2W	33	arm, events	0 / 52		R0002409:Results
NCT06256562	A4	BOFANG_SC_48MG_Q2W	33	arm, events	0 / 64		R0002409:Results
NCT06256562	A5	BOFANG_SC_24MG_QW	33	arm, events	0 / 53		R0002409:Results
NCT06256562	A6	PLACEBO	33	arm, events	0 / 66		R0002409:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab